FHTX
Foghorn Therapeutics Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $5.25 | $3.82 | -27% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $5.60 | $3.82 | -32% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $5.60 | $3.82 | -32% |
| Point72 Asset Management | Q3 2024(8Q snapshot) | 7Q | $5.60 | $3.82 | -32% |
| AQR Capital Management | Q2 2025(8Q snapshot) | 4Q | $4.31 | $3.82 | -11% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Two Sigma Investments | Q1 2026 | Q2 2026 | → $3.79 | -32% |
| D.E. Shaw | Q3 2024 | Q3 2025 | → $5.14 | -8% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Foghorn Therapeutics Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Apr 13, 2026 — the most recent Form 4 on file — not from today.
- Form 40001828724-26-000005Apr 13, 2026
- Form 40001363984-26-000004Feb 24, 2026
- Form 40001828724-26-000003Feb 6, 2026
- Form 40001939167-26-000002Feb 2, 2026
- Form 40001831755-26-000002Feb 2, 2026
- Form 40001760104-26-000002Feb 2, 2026
- Form 40002035647-26-000002Feb 2, 2026
- Form 40001831749-26-000002Feb 2, 2026
- Form 40001193125-26-014218Jan 15, 2026
- Form 40001872280-25-000003Nov 17, 2025
- Form 40001562180-25-004909Jun 17, 2025
- Form 40001562180-25-004908Jun 17, 2025
- Form 40001562180-25-004907Jun 17, 2025
- Form 40001562180-25-004906Jun 17, 2025
- Form 40001562180-25-004902Jun 17, 2025
Fundamentals
XBRL · Foghorn Therapeutics Inc.Annual figures sourced directly from Foghorn Therapeutics Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Foghorn Therapeutics Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 7, 2026
- 8-KMaterial eventMay 7, 2026
- DEF 14AProxy statementApr 30, 2026
- 8-KMaterial eventApr 21, 2026
- 10-KAnnual reportMar 11, 2026
- 8-KMaterial eventMar 11, 2026
- 8-KMaterial eventFeb 23, 2026
- 8-KMaterial eventJan 12, 2026
- 8-KMaterial eventDec 4, 2025
- 8-KMaterial eventNov 7, 2025
- 10-QQuarterly reportNov 5, 2025
- 8-KMaterial eventNov 5, 2025
- 8-KMaterial eventOct 30, 2025
- 8-KMaterial eventSep 2, 2025
- 10-QQuarterly reportAug 5, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Two Sigma Investments | Q1 2026 | Q2 2026 | $5.56 | $3.79 | -32% |
| Citadel Advisors | Q4 2025 | open | $4.69 | $3.82 | -19% |
| AQR Capital Management | Q2 2025 | open | $4.31 | $3.82 | -11% |
| Citadel Advisors | Q3 2024 | Q1 2025 | $5.60 | $6.13 | +9% |
| D.E. Shaw | Q3 2024 | Q3 2025 | $5.60 | $5.14 | -8% |
| Millennium Management | Q3 2024 | open | $5.60 | $3.82 | -32% |
| Point72 Asset Management | Q3 2024 | open | $5.60 | $3.82 | -32% |
| Renaissance Technologies | Q3 2024 | open | $5.25 | $3.82 | -27% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.